

Serial no. 08/921,060

Attorney Docket no. 27693-01013

CLAIM LISTING

1-23. (Canceled)

24. (Currently amended) A method of inducing B-cell depletion in a human patient having a B-cell disorder comprising administering a B-cell depleting effective amount of a non-radioiodinated chimeric anti-CD20 antibody to the patient, wherein a single administration of the said chimeric anti-CD20 antibody when administered by itself to a subject at a dosage of 0.4 mg/kg body weight 10 mg/m² results in is capable of causing depletion of greater than 90% of peripheral B cells in the subject within about 24 hours post treatment infusion of said chimeric anti-CD20 antibody and of maintaining such depletion for at least two weeks after the administration.

25-30. (Canceled)

31. (Previously presented) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11.

32. (Previously presented) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable light sequence corresponding to SEQ ID NO: 7.

33. (Previously presented) The method of claim 24 which further includes the administration of at least one chemotherapeutic agent.

34. (Previously presented) The method of claim 33 wherein said at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, vincristine and prednisone.

[02 JUNE 2005 – PAGE 2]

Serial no. 08/921,060

Attorney Docket no. 27693-01013

35-40. (Canceled)

41. (Previously presented) The method of claim 24 which further includes the administration of a radiolabeled anti-CD20 antibody.

42. (Previously presented) The method of claim 41 wherein said radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

43. (Previously presented) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11 and the variable region light sequence corresponding to SEQ ID NO: 7, or CD20 binding fragment thereof.

44. (Previously presented) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the complementarity determining regions of SEQ ID NOs: 7 and 11.

[02 JUNE 2005 – PAGE 3]